Purpose of this Study
We are doing this study to find out if an experimental drug called APL-5125 (the study drug) is a safe and effective for people with select types of gastrointestinal cancer. We are also trying to find the best dose of APL-5125 to use.
Who Can Participate?
Eligibility
Adults ages 18+ who have locally advanced or metastatic tumors of one of the following types:<ul>
<li>Colorectal carcinoma</li>
<li>Cholangiocarcinoma</li>
<li>Appendiceal adenocarcinoma</li></ul>
For more information about this study, contact the study team at 919-668-1861.
<li>Colorectal carcinoma</li>
<li>Cholangiocarcinoma</li>
<li>Appendiceal adenocarcinoma</li></ul>
For more information about this study, contact the study team at 919-668-1861.
What is Involved?
If you choose to join this study, you will:<ul>
<li>Take the study drug, APL-5125, by mouth every day</li>
<li>Have your tumor biopsied</li>
<li>Give blood and urine samples</li>
<li>Have regular CT or MRI scans</li></ul>
<li>Take the study drug, APL-5125, by mouth every day</li>
<li>Have your tumor biopsied</li>
<li>Give blood and urine samples</li>
<li>Have regular CT or MRI scans</li></ul>
Study Details
Full Title
[AP10CP01] A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults with Selected Advanced Solid Tumors
Principal Investigator
John
Strickler
Protocol Number
PRO00115529
NCT ID
NCT06399757
Phase
I/II
Enrollment Status
Open to Enrollment